About PledPharma

PledPharma has an innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments do not exist.

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need.

Aladote® a first-in-class drug candidate,  is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of a pivotal Phase II/III study for US/EU regulatory submission is being finalized through ongoing regulatory interactions. Aladote® has been granted Orphan Drug Designation in the US.

Emcitate® a first-in-class drug candidate, is being developed for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling. A first clinical trial has been concluded with significant and clinically relevant results. Emcitate® has been granted Orphan Drug Designation in the US and EU.

PledOx®  a first-in-class drug candidate, is being developed to reduce nerve damage associated with chemotherapy. The Phase III POLAR program for the drug candidate PledOx® was prematurely stopped in Q2 2020. Results from POLAR program will determine if further development of PledOx® is warranted via strategic partnerships and is expected to be announced in Q4 2020.

PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019.

Aladote®

- protects the liver

Prevents acute liver failure in paracetamol poisoning.

Emcitate®

- restores signaling

Restores thyroid hormone signaling in cells with defect MCT8 transporter.

PledOx®

- protects the peripheral nerves

Protection against the nerve damage that often occurs in connection with chemotherapy.

Share

Twitter
LinkedIn

Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com